Actuate Therapeutics, Inc. Common stock
$2.62
▼
-0.4%
2026-04-21 05:04:00
actuatetherapeutics.com
NGM: ACTU
Explore Actuate Therapeutics, Inc. Common stock stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$54.77 M
Current Price
$2.62
52W High / Low
$11.99 / $1.58
Stock P/E
—
Book Value
$0.34
Dividend Yield
—
ROCE
-270.08%
ROE
-5.54%
Face Value
—
EPS
$-1.06
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
12
Beta
—
Debt / Equity
—
Current Ratio
2.39
Quick Ratio
2.39
Forward P/E
-1.71
Price / Sales
—
Enterprise Value
$27.62 M
EV / EBITDA
—
EV / Revenue
—
Rating
Strong Buy
Target Price
$17.78
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Tonix Pharmaceuticals Holding Corp. | $14.34 | — | $184.59 M | — | -49.81% | -64.48% | $69.97 / $11.6 | $19.17 |
| 2. | Psyence Biomedical Ltd. | $11.3 | 30.05 | $7.77 M | — | -54.49% | -74.29% | $468.38 / $1.92 | $39.62 |
| 3. | Tectonic Therapeutic, Inc. | $28.76 | — | $554.1 M | — | -33.43% | -37.82% | $36.03 / $14.39 | $13.41 |
| 4. | Evommune, Inc. | $27.97 | — | $988.7 M | — | -39.16% | -54.42% | $33.2 / $13.88 | $6.52 |
| 5. | Pharvaris N.V. | $28.97 | — | $1.86 B | — | -54.28% | -65.19% | $29.89 / $13.6 | $5.56 |
| 6. | Incyte Corporation | $97.69 | 15.26 | $19.46 B | — | 24.67% | 29.87% | $112.29 / $56.13 | $26.04 |
| 7. | AbCellera Biologics Inc. | $3.91 | — | $1.22 B | — | -15.72% | -14.47% | $6.51 / $1.94 | $3.22 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -4.69 M | -5.47 M | -5.97 M | -6.37 M | -6.56 M | — |
| Net Profit | -4.55 M | -5.41 M | -5.95 M | -6.32 M | -6.45 M | — |
| EPS in Rs | -0.19 | -0.23 | -0.25 | -0.27 | -0.27 | -0.55 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -22.5 M | -25.16 M | -24.97 M | -20.21 M |
| Net Profit | -22.23 M | -27.29 M | -24.74 M | -20.16 M |
| EPS in Rs | -0.94 | -1.15 | -1.04 | -0.85 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 14.04 M | 9.32 M | 3 M | 20.48 M |
| Total Liabilities | 6.11 M | 9.21 M | 102.62 M | 95.79 M |
| Equity | 7.92 M | 0.1 M | -99.63 M | -75.31 M |
| Current Assets | 13.64 M | 9.21 M | 3 M | 20.48 M |
| Current Liabilities | 5.71 M | 8.8 M | 6.92 M | 4.34 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -19.21 M | -21.84 M | -21.63 M | -17.79 M |
| Investing CF | — | — | — | — |
| Financing CF | 23.72 M | 27.53 M | 4.13 M | 19.26 M |
| Free CF | -19.21 M | -21.84 M | -21.63 M | -17.79 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 18.54% | -10.27% | -22.74% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.